On May 24, 2016 Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) reported that Genentech, a member of the Roche Group, has extended its integrated drug discovery alliance with Evotec for a further three years to discover novel small molecule therapeutics (Press release, Evotec, MAY 24, 2016, View Source [SID:1234512721]). Schedule your 30 min Free 1stOncology Demo! The collaboration initiated in May 2010 was renewed in 2013 and this second extension further validates the value of Evotec’s state-of-the-art technology platform and broad expertise in drug discovery. Activities performed within the collaboration include pharmacology, screening, chemistry, proteomics and structural biology.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are delighted that once again we have extended this fruitful collaboration beyond its 7th year and this latest extension is validation of the value Evotec brings to this partnership. With an increasing portfolio of activities, the scientific teams from both companies are working closely together to effectively and efficiently advance Genentech’s discovery projects."
No financial details were disclosed.